Business Wire

Global Flow Diversion Aneurysm Treatment Market Analysis & Forecasts 2018-2022, With an Expected CAGR of 14% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Flow Diversion Aneurysm Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The analysts forecast the Global Flow Diversion ...
Business Wire

Global Flow Diversion Aneurysm Treatment Market 2018-2022 to Post a CAGR of 14% | Technavio

LONDON--(BUSINESS WIRE)--The global flow diversion aneurysm treatment market is expected to post a CAGR of 14% during the period 2018-2022, according to the latest market research report by Technavio.
TCTMD

NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

LOS ANGELES, NeuroSigma ®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its Thin Film Nitinol (TFN) flow diverter were presented on ...
Healthline

What Is a Pipeline Stent for Brain Aneurysms?

A pipeline stent is a treatment for a brain aneurysm. It’s a minimally invasive procedure that blocks blood flow through the affected part of the blood vessel. Doctors treat brain aneurysms at risk of ...
Business Insider

Steripath Gen2, Next Generation Initial Specimen Diversion Device, Offers An Advanced Approach to Virtually Eliminating Blood Culture Contamination

SEATTLE, Aug. 30, 2018 /PRNewswire/ -- Magnolia Medical Technologies today announced the successful national launch and adoption of Steripath® Gen2. The next generation Initial Specimen Diversion ...
KTLA

Magnolia Medical Expands Steripath® Micro Initial Specimen Diversion Device® (ISDD®) Product Family with New FDA 510(k) Clearance

Designed in collaboration with leading adult and children's hospitals, Steripath Micro is the only FDA 510(k)-cleared low-diversion volume device platform with a specific indication to reduce blood ...